ArticleBMC ophthalmology2026
Treatment of vernal keratoconjunctivitis simulating total limbal stem cell deficiency: a case report.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere vernal keratoconjunctivitis (VKC) can lead to total limbal stem cell deficiency (LSCD), a condition characterized by conjunctivalization of the cornea and neovascularization that often results in severe vision loss and typically requires surgical intervention. This report presents a novel case where a condition clinically simulating total LSCD, induced by chronic inflammation from VKC, was reversed using only anti-inflammatory therapy. CASE PRESENTATION: A 15-year-old male with a 7-year history of inadequately managed VKC presented with typical signs of clinically apparent total LSCD in both eyes. Clinical examination revealed diffuse corneal conjunctivalization, superficial neovascularization, and visual acuity reduced to counting fingers. The patient was treated with a topical regimen consisting of 0.5% loteprednol, 0.1% tacrolimus, and preservative-free artificial tears. Over 7 months of continuous treatment, the corneas regained significant transparency. Notably, the patient experienced a recurrence of corneal conjunctivalization at month 24 after self-discontinuing medication at month 23, which was again successfully reversed by resuming the anti-inflammatory therapy.
conclusionsThis case demonstrates that severe functional LSCD secondary to VKC can be successfully reversed through intensive, non-surgical anti-inflammatory therapy. Our findings highlight the critical importance of controlling chronic inflammation and suggest that in selected cases of inflammatory or functional LSCD, exhaustive medical management should be prioritized before considering surgical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.